WallStSmart
GRI

GRI Bio Inc.

NASDAQ: GRI · HEALTHCARE · BIOTECHNOLOGY

$1.63
+2.85% today

Updated 2026-10-28

Market cap
$3.55M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-14.53
Dividend yield
—
52W range
$1 – $64
Volume
0.3M

GRI Bio Inc. (GRI) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item20182019202020212022202320242025
Total assets$639231.00$4.28M$955000.00$218000.00$383000.00$2.96M$5.74M$8.67M
Cash & equivalents$612652.00$3.82M$109000.00$90000.00$9000.00$1.81M$5.03M$8.23M
Current assets$637639.00$3.92M$674000.00$96000.00$312000.00$2.93M$5.62M$8.59M
Total liabilities$486292.00$1.06M$2.41M$4.94M$2.01M$2.70M$1.71M$2.66M
Current liabilities$486292.00$807498.00$2.23M$4.88M$1.99M$2.70M$1.64M$2.64M
Long-term debt————————
Shareholder equity$152939.00$3.21M$-1.45M$-4.72M$-1.63M$259000.00$4.03M$6.01M
Retained earnings$-4.31M$-7.78M$-12.60M$-15.28M$-18.50M$-31.53M$-39.74M$-51.70M
Accounts receivable————————
Inventory————————
Goodwill————————

Frequently asked questions

How much free cash flow does GRI generate?

GRI produced $-10.19M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is GRI's balance sheet healthy?

GRI holds $8.23M in cash and equivalents against — in long-term debt, on $6.01M of shareholder equity. That debt is best read against the cash flow the business throws off each year.